1925results about How to "Avoid pain" patented technology

Methods of treatment of tissue with electromagnetic radiation (EMR) to produce lattices of EMR-treated islets in the tissue are disclosed. Also disclosed are devices and systems for producing lattices of EMR-treated islets in tissue, and cosmetic and medical applications of such devices and systems.

Systems, devices and methods for determining the concentration of physiological fluid analytes are provided. The subject systems have a plurality of biosensor devices present on a disposable cartridge. Each biosensor device includes a biosensor and a skin penetration means. In practicing the subject methods, a movement means of the device is used to move each biosensor device in a first direction that provides for penetration of the skin-piercing means into a skin layer followed by movement of the biosensor in a second direction that provides for removal of the skin-piercing means from the skin layer, where this movement profile provides for physiological fluid access and analyte concentration determination by the analyte sensor means. The subject systems, devices and methods for using the same find use in determining the concentration of a variety of different physiological fluid analytes, and are particularly suited for use in detection of physiological fluid glucose concentration.

The invention relates to an agent specific for peripheral sensory afferents. The agent may inhibit the transmission of signals between a primary sensory afferent and a projection neuron by controlling the release of at least one neurotransmitter or neuromodulator from the primary sensory afferent. The agent may be used in or as a pharmaceutical for the treatment of pain, particularly chronic pain.

Topical compositions and methods for treating pain. The invention provides oil-in-water emulsions comprising an antidepressant; an NMDA-receptor antagonists; a lipophilic component; water; and a surfactant. The compositions induce a local-anesthetic effect when topically administered to intact skin thereby treating or preventing pain, for example, neuropathic pain.

A class of novel agents that are able to modify nociceptive afferent function is provided. The agents may inhibit the release of neurotransmitters from discrete populations of neurones and thereby reduce or preferably prevent the transmission of afferent pain signals from peripheral to central pain fibers. They comprise a galactose-binding lectin linked to a derivative of a clostridial neurotoxin. The derivative of the clostridial neurotoxin comprises the L-chain, or a fragment thereof, which includes the active proteolytic enzyme domain of the light (L) chain, linked to a molecule or domain with membrane translocating activity. The agents may be used in or as pharmaceuticals for the treatment of pain, particularly chronic pain.

Methods for treating female sexual dysfunction are provided. A pharmaceutical composition containing a vasoactive agent selected from vasoactive intestinal potypeptide (VIP) and VIP agonists is administered to the vagina and / or vulvar region of the individual undergoing treatment. The formulations are also useful for improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. Pharmaceutical formulations and kits are also provided.

Disclosed is a folding chair comprising a frame and a seat sheet, which has means for protecting a user's vertebral column and means for expanding the seat to improve its seating comfort and stability. The expanding means are connected to both sides of the seat, and the protecting means is coupled at its opposite ends to armrests, upper portions of frame elements or the expanding means. The expanding means are hanged on projections formed by bending upper portions of the front frame elements. The protecting means is held at a certain height on a back rest of the chair but being allowed to be laterally moved by holding means, thereby enabling length of the protecting means to be adjusted. The folding chair may have one or more means for protecting a user's vertebral column.

Systems and devices for dynamically stabilizing the spine are provided. The systems include a superior component for attachment to a superior vertebra of a spinal motion segment and an inferior component for attachment to an inferior vertebral of a spinal motion segment. The interconnection between the two components enables the spinal motion segment to move in a manner that mimics the natural motion of the spinal motion segment while substantially offloading the facet joints of the spine. Methods are also provided for stabilizing the spine and for implanting the subject systems.

Medical devices, systems, and methods for pain management and other applications may apply cooling with at least one probe inserted through an exposed skin surface of skin. The cooling may remodel one or more target tissues so as to effect a desired change in composition of the target tissue and / or a change in its behavior, often to interfere with transmission of pain signals along sensory nerves. Alternative embodiments may interfere with the function of motor nerves, the function of contractile muscles, and / or some other tissue included in the contractile function chain so as to inhibit muscle contraction and thereby alleviate associated pain. In some embodiments, other sources of pain such as components of the spine (optionally including herniated disks) may be treated.

A method is provided for enhancing a female individual's sexual desire and responsiveness. The method involves administration of a pharmaceutical formulation containing an effective amount of an androgenic agent, wherein administration is on an as-needed basis rather than involving chronic pharmacotherapy. Local delivery may be accomplished via administration to the vagina, vulvar area or urethra of the individual, although oral administration is preferred for those androgenic agents that are orally active. Formulations and kits for carrying out the method are provided as well.

The invention relates to an agent specific for peripheral sensory afferents. The agent may inhibit the transmission of signals between a primary sensory afferent and a projection neutron by controlling the release of at least one neurotransmitter or neuromodulator from the primary sensory afferent. The agent may be used in or as a pharmaceutical for the treatment of pain, particularly chronic pain.

The present invention relates to a portable binder with a rotating frame, comprising a pedestal and a rotating frame, wherein the pedestal has a base and on both sides of the base, there is a lacing hole to be reeved by a binding tape, which can be used by tightening it around arms. An axle hole penetrates through the base to combine a coaxial connection shaft, and on the base, a supporting plate is established concavely on both sides to cover a proposed electronic device, while an axial part is established to interconnect the coaxial connection shaft on the supporting plate, and on the axial part, there is a rotation shaft that can be coaxially connected with the coaxial connection shaft. When the binding tape reeving the base is fastened around users' arms, the body of the rotating frame can be utilized to fix the electronic device, thus achieving the effect of making the electronic device portable when users go out. Besides, the design of adjusting the visual angle by using the rotating frame makes it convenient to use the portable binder disclosed in the present invention.

The invention relates to biocompatible modified starch sponge and use of the biocompatible modified starch sponge as a hemostatic material, an anti-adhesion material, a material for promoting tissue healing, a surgical sealant or a wound tissue adhesive. Modified starch is one or a combination of more than one among pre-gelatinized starch, acid modified starch, dextrin, oxidized starch, esterified starch, etherified starch, crosslinked starch, grafted starch and composite modified starch. The sponge is prepared by vacuum freeze drying of the modified starch and other biocompatible hemostatic material, coagulant, plasticizer and so on. The biocompatible modified starch sponge has the advantages that the biocompatible modified starch sponge has flexible form and good biocompatibility, can be directly acted on bloody wound surfaces, avoids the conditions of hypersusceptibility, infection and difficult healing of wounds caused by adoption of hemostatic materials such as animal source / human source collagens, obviously improves the water absorption speed, has larger viscosity, forms a zymoplastic mixture which has good adhesion, calks broken tissues and blood vessels, and is used for hemostasis of active hemorrhage.

The invention discloses an absorbable haemostatic material of a modified starch and a preparation method thereof. The haemostatic material is etherified modified starch or a composition which is formed by one or two or more than two of the etherified modified starch, cross-linked and composite modified starch, with a molecular weight of 15,000 to 2,000,000, a grain diameter of 10-1000Mu m and a water absorbency of 1 time to 100 times. The modified starch absorbable haemostatic material has the advantages that: the haemostatic material with biocompatibility is directly applied to bloody surface of wound to stop bleeding immediately, obviously increase the water absorbency and the water absorbing speed and have more viscosity and viscidity, thereby simultaneously blocking up damaged tissues and blood vessels while stopping bleeding. The haemostatic material is easy to swell or dissolve in water and after stopping bleeding, normal saline is used for washing to eliminate the haemostatic material not participating in stopping bleeding, thus reducing residues in the body, being beneficial to wound healing, and avoiding pains caused by unclosing pledget and bandage. The haemostatic material has the physical and chemical properties of stability, difficult decomposition, long guarantee period, convenient storage, high pressure resistance, low pressure resistance, high temperature resistance, low temperature resistance and difficult change.

The invention relates to an anti-corrosion high-toughness zinc alloy implant material capable of being absorbed by a human body. The anti-corrosion high-toughness zinc alloy implant material comprises the following elemental constituents by mass percent: 0.001-2% of Ce, 0.001-2% of Mg, 0.001-2% of Ca, 0.01-3% of Cu, and the balance of Zn. The zinc alloy material is prepared into a medical implant with absorbability by using a conventional method in the field, especially an intravascular stent, and orthopedic implants (a nail or bone lamella and the like). The zinc alloy material created by the invention has high corrosion resistance and high toughness, and the prepared medical implant can be absorbed by the human body, and is free of a side effect.